Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SanBio Co ( (JP:4592) ) has issued an announcement.
SanBio has approved the issuance of its 36th series of share acquisition rights as part of its stock option program, granting up to 75,000 stock options linked to an equal number of common shares to three employees. The program is designed to strengthen employee motivation, support the recruitment and retention of key talent, and align staff incentives with the company’s medium- to long-term performance, thereby reinforcing corporate value and shareholder interests through equity-based compensation.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1651.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd. is a Japan-listed company on the Tokyo Stock Exchange Growth Market (code 4592). The company operates in the life sciences/biotechnology sector and focuses on developing and commercializing novel therapeutic products, with an emphasis on building long‑term corporate value through securing and retaining highly skilled personnel.
Average Trading Volume: 2,498,103
Technical Sentiment Signal: Sell
Current Market Cap: Yen136.5B
Learn more about 4592 stock on TipRanks’ Stock Analysis page.